Skip to main content

Table 3 Comparison of clinical characteristics in cases whose ICWBIA decreased or increased after six hours of add-on tolvaptan

From: Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study

VariablesICWBIA DecreasedICWBIA IncreasedP (uni)
N17 (57%)13 (43%)
Age, years69 [46–87]65 [51–80]0.325
Sex, M/F9/88/50.721
Background clinical profile
 Child-Pugh-Turcotte B/C11/64/90.139
 MELD score13 [8–23]16 [8–29]0.075
 MELDNa score17 [8–30]21 [13–32]0.047*
 MAP, mmHg81 [65–104]82 [76–106]0.818
Baseline diuretics
 Furosemide, mg/day25 [0–160]20 [0–80]0.589
Spironolactone, mg/day25 [0–100]50 [0–75]0.825
Pre-treatment biochemical studies
 Total bilirubin, mg/dL1.5 [0.3–12.6]3.5 [1.1–8.3]0.040*
 PT-INR1.20 [0.96–1.75]1.33 [1.03–2.42]0.476
 Serum sodium, mmol/L135.6 [123.1–142.8]133 [122.3–40.0]0.368
 Albumin, g/dL2.6 [1.6–3.1]2.3 [1.8–3.9]0.867
 BUN, mg/dL18.2 [5.9–47.1]25.3 [11.9–46.3]0.054
 Serum creatinine, mg/dL0.99 [0.48–2.49]1.01 [0.48–2.13]0.786
 ALT, IU/L20 [7–75]39 [11–69]0.019*
 GGTP, IU/L64 [14–264]95 [11–359]0.315
 AVP, pg/mL1.4 [0.8–5.1]2.3 [1.2–6.3]0.076
 Aldosterone, pg/mL116 [18–407]333 [107–1200]0.012*
 Serum osmolality, mOsm/kg. H2O287 [250–295]280 [273–293]0.659
 Urine osmolality, mOsm/kg. H2O441 [272–691]485 [59–838]0.267
  1. Data are shown as median with the range within brackets, or numbers
  2. Abbreviations: M Male, F Female, MELD Model for end-stage liver disease, Map Mean arterial pressure, PT-INR Prothrombin time- international ratio, BUN Blood urea nitrogen, ALT Alanine transaminase, GGTP γ- glutamyl transpeptidase, AVP Arginine vasopressin
  3. *, P < 0.05; **, P < 0.01